Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, run by SCbio in partnership with MassBio.
This program brings together emerging companies developing next-generation diagnostic and biomarker technologies, alongside industry mentors and ecosystem partners focused on accelerating clinical translation. DRIVE is backed by a network of leading strategic partners — including Eli Lilly, LabCorp, and others across pharma, diagnostics, and health systems — providing participating companies with direct access to industry decision-makers and potential commercialization partners.
Participation in DRIVE supports continued development of our nanosensor-enabled platform within the broader diagnostics and precision medicine landscape, with a focus on advancing strategic partnerships and real-world deployment pathways.